Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial

BACKGROUND: Although effective mRNA vaccines for SARS-CoV-2 infection have been deployed worldwide, their interchangeability could facilitate the scale-up of vaccination programs. The objective of the trial was to assess whether the immune response induced by a heterologous SARS-CoV-2 mRNA primo vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Cécile, Cachanado, Marine, Ninove, Laetitia, Lachatre, Marie, Michon, Jocelyn, Epaulard, Olivier, Maakaroun-Vermesse, Zoha, Chidiac, Christian, Laviolle, Bruno, Aumaitre, Hugues, Assaf, Ady, Lacombe, Karine, Schmidt-Mutter, Catherine, Botelho-Nevers, Elisabeth, Briere, Magali, Boisson, Thomas, Loubet, Paul, Bienvenu, Boris, Bouchaud, Olivier, Touati, Amel, Pereira, Christine, Rousseau, Alexandra, Berard, Laurence, Montil, Melissa, de Lamballerie, Xavier, Simon, Tabassome, Launay, Odile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098199/
https://www.ncbi.nlm.nih.gov/pubmed/35582124
http://dx.doi.org/10.1016/j.eclinm.2022.101444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098199/
https://www.ncbi.nlm.nih.gov/pubmed/35582124
http://dx.doi.org/10.1016/j.eclinm.2022.101444

Ejemplares similares